{
    "nct_id": "NCT03515577",
    "official_title": "Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy",
    "inclusion_criteria": "* Histopathologically proven prostate cancer (PCa)\n* Radical prostatectomy as definitive treatment for PCa\n* Proven biochemical recurrence as defined by American Urological Association (AUA) recommendation: PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after radical prostatectomy\n* PSA values ranging from 0.2 ng/mL to 2 ng/mL\n* No prior salvage therapies (including salvage radiotherapy and/or salvage lymph node dissection)\n* Axumin PET/CT scan already performed or scheduled as best standard of care procedure for suspected disease relapse within 2 weeks before or after intended 68Ga-PSMA-11 PET/CT\n* Karnofsky performance status of â‰¥ 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization [WHO] equivalent)\n* Ability to understand a written informed consent document and the willingness to sign it\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Any change in prostate cancer treatment between Axumin and 68Ga-PSMA PET/CT scan\n* Unable to lie flat, still or tolerate a PET scan",
    "miscellaneous_criteria": ""
}